Addex Therapeutics Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADXN Nasdaq 2836 www.addextherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Addex Therapeutics Ltd

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders - Jun 29th, 2025 11:00 pm
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs - Jun 29th, 2025 11:00 pm
Addex Shareholders Approve All Resolutions at Annual General Meeting - Jun 24th, 2025 11:00 pm
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update - Jun 18th, 2025 11:00 pm
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 - Jun 17th, 2025 11:00 pm
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models - Jun 5th, 2025 11:00 pm
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference - Jun 4th, 2025 11:00 pm
Addex Convenes Annual General Meeting 2025 - Jun 2nd, 2025 11:00 pm
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - May 11th, 2025 11:00 pm
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery - Apr 29th, 2025 11:00 pm
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update - Apr 24th, 2025 11:00 pm
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025 - Apr 23rd, 2025 11:00 pm
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 - Apr 16th, 2025 11:00 pm
Addex to Present at the 2025 Swiss Equities Baader Conference - Jan 7th, 2025 11:00 pm
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 21st, 2024 11:00 pm
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 - Nov 10th, 2024 11:00 pm
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update - Sep 29th, 2024 11:00 pm
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit - Sep 18th, 2024 11:00 pm
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 11:00 pm
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration - Aug 26th, 2024 11:00 pm